{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:33Z","timestamp":1788437913615,"version":"build-2803163510"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Int Soc Prev Community Dent"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>\n                    <jats:sc>Abstract<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Semaglutide, a glucagon-like peptide-1-receptor agonist, is widely used for the management of type-2 diabetes mellitus and obesity. Despite its increasing clinical use, the drug\u2019s oral adverse effect profile remains inadequately characterized. This narrative review aimed to analyze the current evidence on semaglutide-associated oral adverse effects, with emphasis on mechanistic pathways, integration of pharmacovigilance and clinical data, and emerging implications for oral health and dental practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar. Keywords related to semaglutide and oral adverse effects were used. Eligible studies included clinical trials, pharmacovigilance analyses, observational studies, case reports, and preclinical research reporting oral adverse effects or relevant mechanistic insights. Studies lacking oral health correlates were excluded. Findings were narratively reviewed in accordance with Scale for the Assessment of Narrative Review Articles guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Xerostomia or hyposalivation is the most consistently reported oral adverse effect, although its prevalence varies across studies. However, xerostomia often occurs secondarily to gastrointestinal symptoms including nausea, reduced oral intake, and delayed gastric emptying. Additional manifestations included dysgeusia, dry throat, oral paresthesia or hypoesthesia, halitosis, frothy saliva, and increased dental caries. Pharmacovigilance data show significant signals for dry mouth and altered taste. Case-series confirm semaglutide-associated hyposalivation. Limited evidence suggests increased susceptibility to oral candidiasis. Early experimental and observational data indicate potential modulatory effects on inflammation, tissue repair, and bone metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Semaglutide therapy is associated with oral adverse effects, mainly xerostomia and sensory disturbances, which may compromise oral health. Awareness of these outcomes highlights the need for interdisciplinary oral health monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jispcd.jispcd_5_26","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:00:33Z","timestamp":1783677633000},"page":"331-340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Oral Adverse Effects of Semaglutide Therapy: A Narrative Review"],"prefix":"10.4103","volume":"16","author":[{"given":"Abeer S.","family":"Al-Zawawi","sequence":"first","affiliation":[{"name":"Department of Periodontics and Community Dentistry, College of Dentistry, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"CIT0001-20260903","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: A review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"CIT0002-20260903","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer","year":"2015","journal-title":"Postgrad Med"},{"key":"CIT0003-20260903","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"CIT0004-20260903","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/healthcare12090898","article-title":"Oral health education in patients with diabetes: A systematic review","volume":"12","author":"Petropoulou","year":"2024","journal-title":"Healthcare"},{"key":"CIT0005-20260903","first-page":"1381","article-title":"Oral manifestations of systemic disease","volume":"82","author":"Chi","year":"2010","journal-title":"Am Fam Physician"},{"key":"CIT0006-20260903","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2014.02.007","article-title":"Oral manifestations in patients with neurofibromatosis type-1: A comprehensive literature review","volume":"91","author":"Javed","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"CIT0007-20260903","doi-asserted-by":"crossref","first-page":"e36730","DOI":"10.1097\/MD.0000000000036730","article-title":"Semaglutide-associated hyposalivation: A report of case series","volume":"102","author":"Mawardi","year":"2023","journal-title":"Medicine"},{"key":"CIT0008-20260903","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 agonists: A review for emergency clinicians","volume":"78","author":"Long","year":"2024","journal-title":"Am J Emerg Med"},{"key":"CIT0009-20260903","doi-asserted-by":"crossref","first-page":"e0323","DOI":"10.1097\/HC9.0000000000000323","article-title":"Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models","volume":"7","author":"Bhattacharjee","year":"2023","journal-title":"Hepatol Commun"},{"key":"CIT0010-20260903","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/a-2550-6470","article-title":"Therapeutic potential of the novel GLP-1 receptor agonist semaglutide in alcohol use disorder","volume":"58","author":"Liu","year":"2025","journal-title":"Pharmacopsychiatry"},{"key":"CIT0011-20260903","first-page":"17","article-title":"Possible adverse effects (AEs) of semaglutide (ozempic) administration for the latest investigation","volume":"5","author":"Bando","year":"2024","journal-title":"J Diabetes Res"},{"key":"CIT0012-20260903","first-page":"1077","article-title":"Oral semaglutide: Balancing promising therapeutics with adverse effects and access barriers","volume":"26","author":"Gunning","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"CIT0013-20260903","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/lary.32061","article-title":"Otolaryngologic side effects of GLP-1 receptor agonists","volume":"135","author":"Khan","year":"2025","journal-title":"Laryngoscope"},{"key":"CIT0014-20260903","first-page":"441","article-title":"Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States","volume":"31","author":"Liu","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"CIT0015-20260903","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3390\/ph15121518","article-title":"Effect of anti-diabetic medications on dental implants: A scoping review of animal studies and their relevance to humans","volume":"15","author":"Tan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"CIT0016-20260903","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13679-025-00667-3","article-title":"A multidisciplinary perspective on semaglutide treatment and medical nutrition therapy in obesity management","volume":"14","author":"Barrea","year":"2025","journal-title":"Curr Obes Rep"},{"key":"CIT0017-20260903","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 analogues and agonists on the gut microbiota: A systematic review","volume":"17","author":"Gofron","year":"2025","journal-title":"Nutrients"},{"key":"CIT0018-20260903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integrity Peer Rev"},{"key":"CIT0019-20260903","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/00325481.2020.1788340","article-title":"Practical guidance for use of oral semaglutide in primary care: A narrative review","volume":"132","author":"Morales","year":"2020","journal-title":"Postgrad Med"},{"key":"CIT0020-20260903","doi-asserted-by":"crossref","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol"},{"key":"CIT0021-20260903","doi-asserted-by":"crossref","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"CIT0022-20260903","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/dom.14571","article-title":"Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials","volume":"24","author":"Yamada","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"CIT0023-20260903","doi-asserted-by":"crossref","first-page":"e084190","DOI":"10.1136\/bmjopen-2024-084190","article-title":"Adverse effects with semaglutide: A protocol for a systematic review with meta-analysis and trial sequential analysis","volume":"14","author":"Sillassen","year":"2024","journal-title":"BMJ Open"},{"key":"CIT0024-20260903","doi-asserted-by":"crossref","first-page":"459","DOI":"10.15537\/smj.2025.46.5.20250126","article-title":"Clinical studies on anti-obesity medications in Arab countries","volume":"46","author":"AlOtaibi","year":"2025","journal-title":"Saudi Med J"},{"key":"CIT0025-20260903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: Double-edged sword with risks and benefits","volume":"8","author":"Pillarisetti","year":"2025","journal-title":"Arch Intern Med Res"},{"key":"CIT0026-20260903","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5937\/arhfarm74-50625","article-title":"Pharmacotherapy of obesity: State of the art and perspectives","volume":"74","author":"Si\u0107ovi\u0107","year":"2024","journal-title":"Arhiv za farmaciju"},{"key":"CIT0027-20260903","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.clnesp.2025.01.056","article-title":"Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"66","author":"Chen","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"CIT0028-20260903","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"CIT0029-20260903","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3390\/nu17142349","article-title":"Clinical effectiveness of oral semaglutide in women with type 2 diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy)","volume":"17","author":"Reyes-Garcia","year":"2025","journal-title":"Nutrients"},{"key":"CIT0030-20260903","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"CIT0031-20260903","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/dom.15339","article-title":"Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies","volume":"26","author":"Rosenstock","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"CIT0032-20260903","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"CIT0033-20260903","first-page":"100340","article-title":"Anti-inflammatory benefits of semaglutide: State of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"CIT0034-20260903","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cmet.2026.01.008","article-title":"Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism","volume":"38","author":"Qin","year":"2026","journal-title":"Cell Metab"},{"key":"CIT0035-20260903","doi-asserted-by":"crossref","first-page":"1539411","DOI":"10.3389\/fphar.2025.1539411","article-title":"Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt\/LRP5\/\u03b2-catenin signaling pathway","volume":"16","author":"Tian","year":"2025","journal-title":"Front Pharmacol"},{"key":"CIT0036-20260903","first-page":"e95792","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in diabetes and obesity: Implications for periodontology and family dentistry","volume":"17","author":"Almohammad","year":"2025","journal-title":"Cureus"},{"key":"CIT0037-20260903","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12015-025-11002-7","article-title":"The influence of GLP-1 agonists on human mesenchymal stem cells: A systematic review","volume":"22","author":"Weber","year":"2026","journal-title":"Stem Cell Rev Rep"},{"key":"CIT0038-20260903","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jre.13410","article-title":"glucagon-like peptide 1 receptor agonists (GLP-1RAs) improve periodontal and peri-implant health in type 2 diabetes mellitus","volume":"60","author":"Ahmad","year":"2025","journal-title":"J Periodontal Res"},{"key":"CIT0039-20260903","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.rce.2022.03.009","article-title":"Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus","volume":"222","author":"Ares-Blanco","year":"2022","journal-title":"Rev Clin Esp"},{"key":"CIT0040-20260903","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14740338.2023.2172159","article-title":"Gastrointestinal disorders potentially associated with Semaglutide: An analysis from the Eudravigilance Database","volume":"22","author":"Cabral Lopes","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"CIT0041-20260903","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"CIT0042-20260903","doi-asserted-by":"crossref","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: An updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"CIT0043-20260903","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management","volume":"6","author":"Holst","year":"2024","journal-title":"Nat Metab"},{"key":"CIT0044-20260903","first-page":"e58564","article-title":"Dry mouth dilemma: A comprehensive review of xerostomia in complete denture wearers","volume":"16","author":"Mhatre","year":"2024","journal-title":"Cureus"},{"key":"CIT0045-20260903","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/biology14121650","article-title":"GLP-1 receptor signaling and oral dysfunction: A narrative review on the mechanistic basis of semaglutide-related oral adverse effects","volume":"14","author":"Bara\u0107","year":"2025","journal-title":"Biology"},{"key":"CIT0046-20260903","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: Mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"CIT0047-20260903","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"CIT0048-20260903","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/life15121862","article-title":"Impact of periodontal host-modulation therapies on oral-gut microbiome axis in periodontitis patients with hematological diseases: A narrative review","volume":"15","author":"Messina","year":"2025","journal-title":"Life"},{"key":"CIT0049-20260903","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"key":"CIT0050-20260903","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/dom.14536","article-title":"Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials","volume":"23","author":"Araki","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"CIT0051-20260903","doi-asserted-by":"crossref","first-page":"1708109","DOI":"10.3389\/fcvm.2026.1708109","article-title":"Research on epicardial adipose tissue as a metabolic therapeutic target in AF: Focus on GLP-1 receptor agonists","volume":"13","author":"Liu","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"CIT0052-20260903","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/receptors3030017","article-title":"Current evidence of natural products against overweight and obesity: Molecular targets and mechanisms of action","volume":"3","author":"Elizalde-Romero","year":"2024","journal-title":"Receptors"},{"key":"CIT0053-20260903","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0\u2009mg vs once-daily liraglutide 1.2\u2009mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"CIT0054-20260903","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jcph.1131","article-title":"Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment","volume":"58","author":"Baekdal","year":"2018","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of International Society of Preventive and Community Dentistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jispcd.jispcd_5_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:01:55Z","timestamp":1788436915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jispcd.jispcd_5_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jispcd.jispcd_5_26","relation":{},"ISSN":["2231-0762","2250-1002"],"issn-type":[{"value":"2231-0762","type":"print"},{"value":"2250-1002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}